Categorie: Stock
GW’s Epidiolex results are worth mentioning
Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate…
OCAT – Q3 2015 – Results are in.
Nyrstar one of my best performing stock for the last 6 months.
Why I think Monsanto (MON) is here to stay!
Nektar reports: “Positive Data from Phase 2 Trial “
GW’s Epidiolex results are worth mentioning
Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate…